Skip to main content
SpringerLink
Log in

Osteoporosis in Men

  • Chapter
  • First Online:
Osteoporosis Rehabilitation

  • 924 Accesses

Abstract

In 2008, the American College of Physicians observed that osteoporosis in men is “substantially underdiagnosed, undertreated, underreported, and inadequately researched.” To a considerable extent, that statement remains true, yet there are signs of increasing clinical and public recognition of the impact of osteoporosis on men, as evidenced in a growing number of research studies on the epidemiology, prevention, and treatment of male osteoporosis. Attention to male osteoporosis is appearing more often in reports of the US National Osteoporosis Foundation and other public agencies. Worldwide, the International Osteoporosis Foundation (IOF) chose to place men at the center of its World Osteoporosis Day in 2014, with the Eberling’s 2014 in-depth publication: Osteoporosis in Men—Why Change Needs to Happen. The report emphasizes that by 2050, more than 900 million men worldwide will have lived beyond age 60.

As life expectancy increases and medical advances have brought a decline in male deaths attributable to heart disease, cancer, and stroke, men have now become more susceptible to chronic disease including osteoporosis. Moreover, in the case of hip fractures and most fragility fractures, men have a higher mortality rate than women—as high as 37 % in the year following a hip fracture. The fact that men experience hip fractures later in life may account for this higher mortality rate. This chapter will focus on the risk factors, diagnosis, prevention, and treatment of osteoporosis specific to men, recognizing that previous chapters have dealt with these issues in a broader context.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Qaseem A, Snow V, Shekelle P, Hopkins Jr R, Forciea MA, Owens DK. Screening for osteoporosis in men: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2008;148(9):680–4.

    Article  PubMed  Google Scholar 

  2. Eberling P. Osteoporosis in men: why change needs to happen. In: International Osteoporosis Foundation. 2014. http://www.iofbonehealth.org/data-publications/reports/osteoporosis-men-why-change-needs-happen. Accessed 15 Apr 2015.

  3. National Institute of Arthritis and Musculoskeletal and Skin Diseases. Osteoporosis in men. Washington, DC: 2012. http://www.niahs.nih.gov/health_infor/bone/osteoporosis.men/asp. Accessed 16 Apr 2015.

  4. Steven JA, Rudd RA. The impact of decreasing U.S. hip fracture rates on future hip fracture estimates. Osteoporos Int. 2013;24(10):2725–8.

    Article  Google Scholar 

  5. Orwoll E. Osteoporosis in men. In: Rosen CJ, editor. Primer on the metabolic bone diseases and disorders of mineral metabolism. Ames: Wiley; 2013. p. 510.

    Google Scholar 

  6. Willson T, Nelson SD, Newbold J, Nelson RE, LaFleur J. The clinical epidemiology of male osteoporosis: a review of the recent literature. Clin Epidemiol. 2015;7:65–76.

    PubMed  PubMed Central  Google Scholar 

  7. Ralston SH, de Crombrugghe B. Genetic regulation of bone mass and susceptibility to osteoporosis. Genes Dev. 2006;20(18):2492–506.

    Article  CAS  PubMed  Google Scholar 

  8. Nilsson M, Sundh D, Ohlsson C, Karlsson M, Mellstrom, Lorentzon M. Exercise during growth and young adulthood is independently associated with cortical bone size and strength in old Swedish men. J Bone Miner Res. 2014;29(8):1798–804.

    Article  Google Scholar 

  9. Warden SJ, Mantilla Roosa SM. Physical activity completed when young has residual bone benefits at 94 years of age: a within-subject controlled study. J Musculoskelet Neuronal Interact. 2014;14(2):239–43.

    CAS  PubMed  PubMed Central  Google Scholar 

  10. Nieves JW, Formica C, Ruffing J, Zion M, Garrett P, Lindsay R, et al. Males have larger skeletal size and bone mass than females, despite comparable bone size. J Bone Miner Res. 2005;20(2):529–35.

    PubMed  Google Scholar 

  11. Seeman E. Pathogenesis of bone fragility in women and men. Lancet. 2002;359(9320):1841–50.

    Article  PubMed  Google Scholar 

  12. Sutton RAL, Dian L, Guy P. Osteoporosis in men: an underrecognized and undertreated problem. B C Med J. 2011;53(10):535–40.

    Google Scholar 

  13. Giusti A, Bianchi G. Treatment of primary osteoporosis in men. Clin Interv Aging. 2014;10:105–15.

    PubMed  PubMed Central  Google Scholar 

  14. Sartorius G, Spasevska S, Idan A, Turner L, Forbes E, Zamojska A. Serum testosterone, dihydrotestosterone, and estradiol concentrations in older men self-reporting very good health: the healthy man study. Clin Endocrinol (Oxf). 2012;77(5):755–63.

    Article  CAS  Google Scholar 

  15. Wu FCW, Tajar A, Beynon J, Pye SR, Silman AJ, Finn JD. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med. 2010;363:123–35.

    Article  CAS  PubMed  Google Scholar 

  16. Falahati-Nini A, Riggs BL, Atkinson EJ, O’Fallon WM, Eastell R, Khosla S. Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. J Clin Invest. 2000;106(12):1553–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Tenover JS. Androgen replacement therapy to reverse and/or prevent age-associated sarcopenia in men. Baillieres Clin Endocrinol Metab. 1998;12(3):419–25.

    Article  CAS  PubMed  Google Scholar 

  18. Mayo Clinic. Male hypogonadism: causes. http://www.mayoclinic.org/diseases-conditions/male-hypogonadism/basics/causes/con-20014235. Accessed 16 Apr 2015.

  19. Banu J. Causes, complications, and treatment of osteoporosis in men. Drug Des Devel Ther. 2013;7:849–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Van Henelrijck M, Garmo H, Michaelsson K, Thorstenson A, Akra O, Stattin P, et al. Mortality following hip fracture for men with prostate cancer. PLOSone. 2013;8(9), e74492. doi:10.1371/journalpone.0074492.

    Article  Google Scholar 

  21. Adler RA, Hochberg MC. Glucocorticoid-induced osteoporosis in men. J Endocrinol Invest. 2011;34(6):481–4.

    Article  CAS  PubMed  Google Scholar 

  22. Rao SS, Budhwar N, Ashfaque A. Osteoporosis in men. Am Fam Physician. 2010;82(5):503–8.

    PubMed  Google Scholar 

  23. Shepherd AJ, Cass AR, Carlson CA, Ray L. Development and internal validation of male osteoporosis risk evaluation score. Ann Fam Med. 2007;5(6):540–6.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Skedros JG, Sybrowsky CL, Stoddard GJ. The osteoporosis self-assessment screening tool: a useful tool for the orthopaedic surgeon. J Bone Joint Surg Am. 2007;89(4):765–72.

    PubMed  Google Scholar 

  25. Cass AR, Shepherd AJ. Validation of the male osteoporosis risk estimation score (MORES) in a primary care setting. J Am Board Fam Med. 2013;26(4):436–44. doi:10.3122/jabfm.2013.04.120182.

    Article  PubMed  Google Scholar 

  26. Watts NB, Adler RA, Bilezikian JP, Drake MT, Eastell Y, Orwoll ES, et al. Osteoporosis in men: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012;97(6):1802–22.

    Article  CAS  PubMed  Google Scholar 

  27. Clinician’s guide to prevention and treatment of osteoporosis. National Osteoporosis Foundation. 2013. p. 20. doi:10.1007/s00198-014-2794-2.

  28. Kanis JA, Bianchi G, Bilezikian JP, Kaufman J-M, Khosla S, Orwoll E, et al. Towards a diagnostic and therapeutic consensus in male osteoporosis. Osteoporos Int. 2011;22(11):2789–98.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. World Health Organization Collaborative Centre for Metabolic Bone Diseases. FRAX: WHO fracture risk assessment tool. University of Sheffield, UK. https://www.shef.ac.uk/FRAX/tool.jsp. Accessed 08 Aug 2015.

  30. Bauer DC, Ewing SK, Cauley JA, Ensrud KE, Cummings SP, Orwoll ES, et al. Quantitative ultrasound predicts hip and non-spine fracture in men: the MrOS study. Osteoporos Int. 2007;18(6):771–7.

    Article  CAS  PubMed  Google Scholar 

  31. Bethel M, Machua W, Carbone LD, Lohr KM. Osteoporosis workup: laboratory studies. http://emedicine.medscape.com/article/330598-workup. Accessed 5 May 2015.

  32. Ryan CS, Petkov VI, Adler RA. Osteoporosis in men: the value of laboratory testing. Osteoporos Int. 2011;22(6):1845–53.

    Article  CAS  PubMed  Google Scholar 

  33. Meier C, Nguyen TV, Center JR, Seibel MJ, Eisman JA. Bone resorption and osteoporotic fractures in elderly men: the Dubbo osteoporosis epidemiology study. J Bone Miner Res. 2005;20(4):579–87.

    Article  PubMed  Google Scholar 

  34. Bauer DC, Garnero P, Harrison SL, Cauley JA, Eastell R, Ensrud K, et al. Biochemical markers of bone turnover, hip bone loss, and fracture in older men: the MrOS study. J Bone Miner Res. 2009;24(12):2032–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Szulc P, Montella A, Delmas PD. High bone turnover is associated with accelerated bone loss but not with increased fracture risk in men aged 50 and over: the prospective MINOS study. Ann Rheum Dis. 2008;67(9):1249–55.

    Article  CAS  PubMed  Google Scholar 

  36. Vasikaran S. Bone turnover markers: the impact of assay standardization on assessing and monitoring osteoporosis. In: American Association for Clinical Chemistry. 2013. https://www.aacc.org/publications/cln/articles/2013/july/bone-turnover-markets. 10 Aug 2015.

  37. Dawson-Hughes B, Harris SS, Krall EA, Dallal GE. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med. 1997;337(10):670–6.

    Article  CAS  PubMed  Google Scholar 

  38. Trivedi DP, Doll R, Khaw KT. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomized double blind controlled trial. BMJ. 2003;326(7387):469. doi:10.1136/bmj.326.7387.469.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Kiel DP, Zhang Y, Hannan MT, Anderson JJ, Baron JA, Felson DT. The effect of smoking at different life stages on bone mineral density in elderly men and women. Osteoporos Int. 1996;6(3):240–8.

    Article  CAS  PubMed  Google Scholar 

  40. Olofsson H, Byberg L, Mohsen R, Mehus H, Lithell H, Michaelsson K. Smoking and the risk of fracture in older men. J Bone Miner Res. 2005;20(7):1208–15.

    Article  PubMed  Google Scholar 

  41. Kim MJ, Shim MS, Kim MK, Lee Y, Shim YG, Chung CH, et al. Effect of chronic alcohol ingestion on bone mineral density in males without liver cirrhosis. Korean J Intern Med. 2003;18(3):174–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Takata S, Yasui N. Disuse osteoporosis. J Med Invest. 2001;48(3–4):147–56.

    CAS  PubMed  Google Scholar 

  43. Nigram Y, Knight J, Jones A. Effects of bedrest: musculoskeletal and immune systems, skin and self-perception. Nurs Times. 2009;105(23):18–22.

    Google Scholar 

  44. Hetland H, Haarbo J, Christiansen C. Low bone mass and high bone turnover in male long distance runners. J Clin Endocrinal Metab. 1993;77(3):770–5.

    CAS  Google Scholar 

  45. MacDougall JD, Webber CE, Martin J, Ormerod S, Chesney A, Younglai EV, et al. Relationship among running mileage, bone density, and serum testosterone in male runners. J Appl Physiol. 1992;73(3):1165–70.

    CAS  PubMed  Google Scholar 

  46. Mussolino ME, Looker AC, Orwell ES. Jogging and bone mineral density in men: results from NHANES III. Am J Public Health. 2001;91(7):1056–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Reents S. Exercise and osteoporosis. In: AthleteInMe.com. 2007–2014. http://www.athleteinme.com/ArticleView.aspx?id=283. 10 Aug 2015.

  48. Herrera A, Lobo-Escolar A, Mateo J, Gil J, Ibarz, Gracia L. Male osteoporosis: a review. World J Orthop. 2012;3(12):223–340.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Drake MT, Clarke B, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc. 2008;83(9):1032–45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Sim IW, Eberling PR. Treatment of osteoporosis in men with bisphosphonates: rationale and latest evidence. Ther Adv Musculoskelet Dis. 2013;5(5):259–67.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Orwoll E, Ettinger M, Weiss S, Miller P, Kendler D, Graham J. Alendronate for the treatment of osteoporosis in men. N Engl J Med. 2000;343(9):604–10.

    Article  CAS  PubMed  Google Scholar 

  52. Planas J, Trilla E, Raventos C, Cecchini L, Orsola A, Salvador C. Alendronate also decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosis. BJU Int. 2009;104(11):1637–40.

    Article  CAS  PubMed  Google Scholar 

  53. Greenspan S. Protecting bone health in men with prostate cancer undergoing ADT. In: Review of endocrinology. 2009. http://bmctoday.net/reviewofendo/2009/02/article.asp?f=review0209_04.php 20 Aug 2015.

  54. Stoch SA, Saag KG, Greenwald M, Sebba AI, Cohen S, Verbruggen N, et al. Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial. J Rheumatol. 2009;36(8):1705–14.

    Article  CAS  PubMed  Google Scholar 

  55. Le Blanc AD, Driscol TB, Shackelford LC, Evans HJ, Rianon NJ, Smith SM. Alendronate as an effective countermeasure to disuse induced bone loss. J Musculoskelet Neuronal Interact. 2002;2(4):335–43.

    Google Scholar 

  56. LeBlanc A, Matsumoto T, Jones J, Shapiro J, Lang T, Shackelford L. Bisphosphonates as a supplement to exercise to protect bone during long-duration space flight. Osteoporos Int. 2013;24(7):2105–14.

    Article  CAS  PubMed  Google Scholar 

  57. Ringe JD, Farahmand P, Faber H, Dorst A. Sustained efficacy of risedronate in men with primary and secondary osteoporosis: result of a 2 year study. Rheumatol Int. 2009;29(3):311–5.

    Article  CAS  PubMed  Google Scholar 

  58. Reid DM, Hughes RA, Laan RFJM, Sacco-Gibson NA, Wenderoth DH, Adami S, et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. J Bone Miner Res. 2000;15(6):1006–13.

    Article  CAS  PubMed  Google Scholar 

  59. Reid DM, Adam S, Devogelaer JP, Chines AA. Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy. Calcif Tissue Int. 2001;69(4):242–7.

    Article  CAS  PubMed  Google Scholar 

  60. Orwoll ES, Binkley NC, Lewiecki EM, Gruntmanis U, Fries MA, Dasic G. Efficacy and safety of monthly ibandronate in men with low bone density. Bone. 2010;46(4):970–6.

    Article  CAS  PubMed  Google Scholar 

  61. Lyles K, Colon-Emetic CS, Magazine JS, Adachi JD, Pieper CF, Matalan C, et al. Zoledronic acid in reducing clinical fracture and mortality after hip fracture. N Engl J Med. 2007;357:1799–809. doi:10.1056/NEJMoa074941.

    Article  CAS  PubMed  Google Scholar 

  62. Erikson EF, Lyles KW, Colon-Emetic CS, Pieper CFR, Magazine JS, Adachi J, et al. Antifracture efficacy and reduction of mortality in relation to timing of the first dose of zoledronic acid after hip fracture. J Bone Miner Res. 2009;24(7):1308–13.

    Article  Google Scholar 

  63. Boonen S, Reginster J-V, Kaufman J-M, Lippunar K, Zanchetta J, Langdahl B, et al. Fracture risk and zoledronic acid therapy in men with osteoporosis. N Engl J Med. 2012;367(18):1714–23.

    Article  CAS  PubMed  Google Scholar 

  64. Orwoll ES, Scheele WH, Paul S, Adami S, Syversen U, Diez-Perez A, et al. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res. 2003;18(1):9–17.

    Article  CAS  PubMed  Google Scholar 

  65. Kaufman JM, Orwoll E, Goemaere S, San Martin J, Hossain A, Dalsky GP, et al. Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos Int. 2005;16(5):510–6.

    Article  CAS  PubMed  Google Scholar 

  66. Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM. The effects of parathyroid hormone, alendronate, and both in men with osteoporosis. N Engl J Med. 2003;349(13):1216–26.

    Article  CAS  PubMed  Google Scholar 

  67. Walker MD, Cusano NE, Sliney Jr J, Romano M, Zhang C, McMahon DJ, et al. Combination therapy with risedronate and teriparatide in male osteoporosis. Endocrine. 2013;44(1):237–46.

    Article  CAS  PubMed  Google Scholar 

  68. Saag KG, Zanchetta JR, Devogelaer JP, Adler RA, Eastell R, See K, et al. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six month results of a randomized, double-blind, controlled trial. Arthritis Rheum. 2009;60(11):3346–55.

    Article  CAS  PubMed  Google Scholar 

  69. Gluer CC, Marin F, Ringe JD, Hawkins F, Moricke R, Papaioannu N, et al. Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs trial. J Bone Miner Res. 2013;28(6):1355–68.

    Article  PubMed  PubMed Central  Google Scholar 

  70. Orwoll E, Teglbjaerg CS, Langdahl BL, Chapuriat R, Czerwinski E, Kendler DL, et al. A randomized, placebo-controlled study of the effects of denosumab for treatment of men with low bone mineral density. J Clin Endocrinol Metab. 2012;97(9):3161–9.

    Article  CAS  PubMed  Google Scholar 

  71. Langdahl BL, Teglbjaerg CS, Ho PR, Chapuriat R, Czerwinski E, Kndler DL, et al. A 24-month study evaluating the efficacy and safety of denosumab for the treatment of men with low bone mineral density: results from the ADAMO trial. J Clin Endocrinol Metab. 2015;100(4):1335–42.

    Article  CAS  PubMed  Google Scholar 

  72. Smith MR, Egerdie B, Hernandez Toriz N, Feldman R, Tammela TLJ, Saad F, et al. Denosumab in men receiving androgen–deprivation therapy for prostate cancer. N Engl J Med. 2009;361(8):745–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Smith MR, Morton RA, Barnette KG, Sieber PR, Malkowicz SB, Rodriquez D, et al. Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer. J Urol. 2013;189(1 Suppl):45–50. 2013.

    Article  Google Scholar 

  74. Thomas D, Henshaw R, Skubitz K, Chawla S, Staddon A, Blay JL, et al. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol. 2010;11(3):275–80.

    Article  CAS  PubMed  Google Scholar 

  75. Chawla S, Henshaw R, Seeger L, Choy E, Blay JY, Farrari S, et al. Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. Lancet Oncol. 2013;14(9):901–8.

    Article  CAS  PubMed  Google Scholar 

  76. Whitaker M, Guo J, Kehoe T, Benson G. Bisphosphonates for osteoporosis—where do we go from here? N Engl J Med. 2012;366(22):2048–51.

    Article  CAS  PubMed  Google Scholar 

  77. Haider A, Meergans U, Traish A, Saad F, Doros G, Lips P, et al. Progressive improvement of T-scares in men with osteoporosis and subnormal serum testosterone levels upon treatment with testosterone over six years. Int J Endocrinol. 2014. doi:10.1155/2014/496948.

    Google Scholar 

  78. Dandona P, Rosenberg MT. A practical guide to male hypogonadism in the primary care setting. J Clin Pract. 2010;64(6):682–96.

    Article  CAS  Google Scholar 

  79. Ie-Wen S, Ebeling PR. Treatment of osteoporosis in men with bisphosphonates: rationale and latest evidence. Ther Adv Muscoloskelet Dis. 2013;5(5):259–67.

    Article  Google Scholar 

  80. Smith MR, Fallon MA, Lee H, Finkelstein JS. Raloxifene to prevent gonadotropin-releasing hormone agonist induced bone loss in men with prostate cancer. J Clin Endocrinol Metab. 2004;89(8):3841–6.

    Article  CAS  PubMed  Google Scholar 

  81. Steiner MS, Patterson A, Israeli R, Barnette KG, Boger R, Price D. Toremifene citrate versus placebo for treatment of bone loss and other complications of androgen deprivation therapy in patients with prostate cancer. J Clin Oncol: Proc 2004 Am Soc Clin Oncol Annu Meet. 2004;22(14S):4597.

    Article  Google Scholar 

  82. Smith MR, Malkowicz SB, Brawer MK, Hancock ML, Morton RA, Steiner MS. Toremifene decreases vertebral fractures in men younger than 80 years receiving androgen deprivation therapy for prostate cancer. J Urol. 2011;186(6):2239–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  83. Negro-Vilar A. Selective androgen receptor modulators (SARMs): a novel approach to androgen therapy for the new millennium. J Clin Endocrinol Metab. 1999;84(10):597–617.

    Article  Google Scholar 

  84. Sieber PR, Keiller DL, Kahnoski RJ, Gallo J, McFadden S. Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer. J Urol. 2004;171(6.1):2272–6.

    Article  CAS  PubMed  Google Scholar 

  85. Ringe JD, Dorst A, Farahmand P. Efficacy of strontium ranelate on bone mineral density in men with osteoporosis. Arzneimittelforschung. 2010;60(5):267–72.

    CAS  PubMed  Google Scholar 

  86. European Medicines Agency. Protelos/Osseor to remain available but with further restrictions. 2014. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/Protelos_and_Osseor/human_referral_prac_000025.jsp&mid=WC0b01ac05805c516f. Accessed 20 Aug 2015.

  87. Berkeley Wellness. A new supplement for old bones. 2015. http://www.berkeleywellness.com/supplements.mineral/articles/new-supplement-old-bones. Accessed 21 Aug 2015.

  88. Drugs for the treatment of osteoporosis: calcitonin and bisphosphonates. Endocrineweb. 2014. http://www.endocrineweb.com/conditions/osteoporosis/newest-drugs-treatment-osteoporosis. 21 Aug 2015.

  89. Trovas GP, Lyritis GP, Galanos A, Raptou P, Constantelou E. A randomized trial of nasal spray salmon calcitonin in men with idiopathic osteoporosis: effects of bone mineral density and bone markers. J Bone Miner Res. 2002;17(3):521–7.

    Article  CAS  PubMed  Google Scholar 

  90. Lyritis GP, Paspati I, Karachalios T, Ioakimidis D, Skarantavos G, Lyritis PG. Pain relief from nasal salmon calcitonin in osteoporotic vertebral crush fractures. A double blind, placebo-controlled clinical study. Acta Orthop Scand Suppl. 1997;276:112–4.

    Article  Google Scholar 

  91. Knopp-Sihota JA, Newburn-Cook CV, Homik J, Cummings GG, Voaklander D. Calcitonin for treating acute and chronic pain of recent and remote osteoporotic vertebral compression fractures: a systematic review and meta-analysis. Osteoporos Int. 2012;23(1):17–38.

    Article  CAS  PubMed  Google Scholar 

  92. Cummings SR, Palermo L, Browner W, Marcus R, Wallace R, Pearson J, et al. Monitoring osteoporosis therapy with bone densitometry: misleading changes and regression to the mean. Fracture Intervention Trial Research Group. JAMA. 2000;283(10):1318–21.

    Article  CAS  PubMed  Google Scholar 

  93. Wheater G, Elshahaly M, Tuck SP, Datta HK, van Laar JM. The clinical utility of bone marker measurements in osteoporosis. J Transl Med. 2013;11:201.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Rehabilitation Medicine, Thomas Jefferson University, Philadelphia, PA, USA

    Christina V. Oleson

Authors
  1. Christina V. Oleson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christina V. Oleson .

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Oleson, C.V. (2017). Osteoporosis in Men. In: Osteoporosis Rehabilitation. Springer, Cham. https://doi.org/10.1007/978-3-319-45084-1_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-45084-1_6

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-45082-7

  • Online ISBN: 978-3-319-45084-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation